desmoteplase novel highly fibrinspecific clotbusting thrombolytic drug development reached phase iii clinical trials danish pharmaceutical company lundbeck owns worldwide rights desmoteplase two large trials started test safe effective treatment patients acute ischaemic stroke disappointing results terminated december lundbeck announced would stop development desmoteplase recombinant form isoform dspa desmodus rotundus salivary plasminogen activator desmoteplase chemical found saliva vampire bats effect catalysing conversion plasminogen plasmin enzyme responsible breaking fibrin blood clots early saliva vampire bat desmodus rotundus known lead interference haemostatic mechanism host dna coding four plasminogen activators present saliva vampire bat completed four recombinant rotundus salivary plasminogen activator alpha desmoteplase investigated structure desmoteplase similar rtpa alteplase contain plasminsensitive cleavage site lysinebinding kringle domain result desmoteplase comparison rtpa high fibrin selectivity v increase catalytic activity absence neurotoxicity apparent negative effect barrier desmoteplase also halflife four rtpa terminal plasma halflife minutes two phase ii trials dias dedas indicated intravenous iv desmoteplase administered three hours onset ischaemic stroke symptoms associated high rate reperfusion low rate symptomatic intracranial haemorrhage doses subsequent trial benefit could shown could explained inclusion substantial number patients mild stroke baseline small mismatch volumes associated vessel post hoc analyses data pooled data dias dedas data showed patients proximal cerebral vessel occlusion highgrade stenosis baseline angiography positive response phase iii trials started planning enroll patients worldwide acute ischaemic stroke participants treated desmoteplase intravenous bolus dose Î¼gkg within three hours stroke symptom onset patients selected occlusion highgrade stenosis timi proximal cerebral arteries assessed magnetic resonance computed tomography angiography wherever possible additional perfusionweighted imaging diffusionweighted imaging assessments done outcomes studies tell whether desmoteplase breakthrough treatment acute ischaemic stroke june lundbeck published press release study revealing neutral results intentiontotreat proportion patients presenting good clinical outcome comparable desmoteplase group placebo group notably lundbeck mentioned analysing per protocol desmoteplase showed effect relative placebo publication final results still awaited disappointing results trial december lundbeck announced would stop development desmoteplase company made writedown million danish current standards treatment allow iv rtpa hours ischaemic stroke time window benefit typically thought outweighed risk brain interarterial approaches thought useful six hours nevertheless ctperfusion scans mriperfusion versus mridiffusion demonstrate even six hours significant ischaemic penumbra brain tissue may salvageable approaches involves mechanical removal clot example merci device penumbra device removable stents like desmoteplase extend iv treatment window hours would allow much larger percentage ischaemic stroke patients receive active thrombolytic treatment including patients delayed getting hospital neurological assessment could make substantial difference stroke outcomes treatment window could also major impact treatment wakeup strokes patient awoke symptoms sure whether stroke occurred within past hours httpsenwikipediaorgwikidesmoteplase